Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L9IA
|
|||
| Former ID |
DCL000816
|
|||
| Drug Name |
Glufosfamide
|
|||
| Synonyms |
Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10; ICD-9: 185] | Phase 3 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Discontinued in Phase 2 | [2] | ||
| Company |
Threshold Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H21Cl2N2O7P
|
|||
| Canonical SMILES |
C(CCl)NP(=O)(NCCCl)OC1C(C(C(C(O1)CO)O)O)O
|
|||
| InChI |
1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1
|
|||
| InChIKey |
PSVUJBVBCOISSP-SPFKKGSWSA-N
|
|||
| CAS Number |
CAS 132682-98-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA synthesis (DNA synth) | Target Info | Inhibitor | [1] |
| Human Deoxyribonucleic acid (hDNA) | Target Info | Modulator | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. | |||
| REF 3 | A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9(8):625-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.